ArticleJournal of cancer research and clinical oncology2014
Heat shock protein 22 overexpression is associated with the progression and prognosis in gastric cancer.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Heat shock protein 22: A new direction for cardiovascular disease (Review).Molecular medicine reports · 2025Review
- Recognition of HSPB8 as a potential therapeutic target for prostate cancer.Frontiers in genetics · 2025Article
- HSPB8-BAG3 chaperone complex modulates cell invasion in intrahepatic cholangiocarcinoma by regulating CASA-mediated Filamin A degradation.Cancer biology & therapy · 2024Article
- Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer.Frontiers in oncology · 2023Article
- Heat Shock Protein 22 in Physiological and Pathological Hearts: Small Molecule, Large Potentials.Cells · 2021Review
- Study of the Relationship between MMP-2 and MMP-9 and Her2/neu Overexpression in Gastric Cancer: Clinico- Pathological Correlations.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer.Cells · 2021Review
- Heat shock protein B8 promotes proliferation and migration in lung adenocarcinoma A549 cells by maintaining mitochondrial function.Molecular and cellular biochemistry · 2021Article
- Small Heat Shock Proteins in Cancers: Functions and Therapeutic Potential for Cancer Therapy.International journal of molecular sciences · 2020Review
- Insights of heat shock protein 22 in the cardiac protection against ischemic oxidative stress.Redox biology · 2020Review
- Identification of a novel anti‑heat shock cognate 71 kDa protein antibody in patients with Kawasaki disease.Molecular medicine reports · 2020Article
- Atorvastatin downregulates HSP22 expression in an atherosclerotic model in vitro and in vivo.International journal of molecular medicine · 2019Article
- The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.Acta pharmacologica Sinica · 2018Article
- Prognostic role of HSPs in human gastrointestinal cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Clinicopathological significance of HSP27 in gastric cancer: a meta-analysis.OncoTargets and therapy · 2017Review
- MicroRNA let-7b suppresses human gastric cancer malignancy by targeting ING1.Cancer gene therapy · 2015Article
- MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2.Cancer gene therapy · 2015Article
- HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer.Cancer gene therapy · 2015Article
- The up-regulation of miR-300 in gastric cancer and its effects on cells malignancy.International journal of clinical and experimental medicine · 2015Article
- Nucleostemin regulates proliferation and migration of gastric cancer and correlates with its malignancy.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe heat shock protein 22 (HSP22) is associated with tumor proliferation and protects tumor cell from apoptosis in many malignancies. However, the role of HSP22 in gastric cancer has not been thoroughly elucidated. The aim was to determine the relationship of HSP22 expression with clinicopathological parameters and prognosis in gastric cancer and estimate the alteration of HSP22 expression after neoadjuvant chemotherapy.
methodsHSP22 and matrix metallopeptidase 9 (MMP-9) antigen expressions were evaluated by immunohistochemistry in 129 gastric carcinoma samples. Univariate and multivariate analyses were performed to determine the association between HSP22 expression and prognosis. The response of HSP22 was assessed in 47 patients who received neoadjuvant chemotherapy.
resultsHSP22 protein expression was significantly associated with tumor size, depth invasion, lymph node metastasis and stage of disease (all P < 0.05). In univariate and multivariate analyses, HSP22 was an independent prognostic factor for both overall survival (OS) and recurrence-free survival (RFS) (P = 0.003 and P = 0.004, respectively). Furthermore, HSP22 overexpression was associated with a poor prognosis in all patients and in patients subgroups stratified by tumor size, depth invasion and lymph node metastasis. In addition, HSP22 was significantly correlated with MMP-9 among 129 gastric cancer tissues (P < 0.001). Patients who had MMP-9 overexpression had poor OS and shorter RFS. Moreover, the alteration of HSP22 was not comparable in 47 patients who underwent neoadjuvant chemotherapy.
conclusionsHSP22 plays an important role on tumor aggressiveness and prognosis and may act as a promising target for prognostic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.